National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, United States.
TyrolPath Obrist Brunhuber GmbH, Zams, Austria.
Front Immunol. 2022 Jun 15;13:916686. doi: 10.3389/fimmu.2022.916686. eCollection 2022.
Antibody response following Omicron infection is reported to be less robust than that to other variants. Here we investigated how prior vaccination and/or prior infection modulates that response. Disease severity, antibody responses and immune transcriptomes were characterized in four groups of Omicron-infected outpatients (n=83): unvaccinated/no prior infection, vaccinated/no prior infection, unvaccinated/prior infection and vaccinated/prior infection. The percentage of patients with asymptomatic or mild disease was highest in the vaccinated/no prior infection group (87%) and lowest in the unvaccinated/no prior infection group (47%). Significant anti-Omicron spike antibody levels and neutralizing activity were detected in the vaccinated group immediately after infection but were not present in the unvaccinated/no prior infection group. Within two weeks, antibody levels against Omicron, increased. Omicron neutralizing activity in the vaccinated group exceeded that of the prior infection group. No increase in neutralizing activity in the unvaccinated/no prior infection group was seen. The unvaccinated/prior infection group showed an intermediate response. We then investigated the early transcriptomic response following Omicron infection in these outpatient populations and compared it to that found in unvaccinated hospitalized patients with Alpha infection. Omicron infected patients showed a gradient of transcriptional response dependent upon whether or not they were previously vaccinated or infected. Vaccinated patients showed a significantly blunted interferon response as compared to both unvaccinated Omicron infected outpatients and unvaccinated Alpha infected hospitalized patients typified by the response of specific gene classes such as OAS and IFIT that control anti-viral responses and IFI27, a predictor of disease outcome.
据报道,与其他变体相比,感染奥密克戎后的抗体反应较弱。在这里,我们研究了先前的疫苗接种和/或先前的感染如何调节这种反应。我们对 83 例奥密克戎感染门诊患者(未接种/无既往感染、接种/无既往感染、未接种/既往感染和接种/既往感染)的疾病严重程度、抗体反应和免疫转录组进行了特征描述。在未接种/无既往感染组(47%)中,无症状或轻症患者的比例最高,在接种/无既往感染组(87%)中最低。感染后立即检测到接种组患者具有显著的抗奥密克戎刺突抗体水平和中和活性,但在未接种/无既往感染组中未检测到。两周内,奥密克戎的抗体水平增加。接种组的奥密克戎中和活性超过了既往感染组。未接种/无既往感染组未见中和活性增加。未接种/既往感染组表现出中等程度的反应。然后,我们研究了这些门诊人群中奥密克戎感染后的早期转录组反应,并将其与未接种疫苗的住院阿尔法感染患者进行了比较。奥密克戎感染患者的转录反应取决于他们是否先前接种过疫苗或感染过,存在梯度。与未接种的奥密克戎感染门诊患者和未接种的阿尔法感染住院患者相比,接种患者的干扰素反应明显减弱,这些患者的特征是特定基因类别的反应,如控制抗病毒反应的 OAS 和 IFIT 以及 IFI27,后者是疾病结果的预测因子。